ArticleCirculation reports2025
Effect of β-Blockers on the Left Ventricular Strain in Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis.
Article in Circulation reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and Safety of Acoramidis in Japanese Adults With Symptomatic Transthyretin Amyloid Cardiomyopathy.Circulation reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although tafamidis is used in patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CM), the effects of β-blockers, one of the conventional heart failure medications, are unclear. Therefore, this study aimed to investigate the effect of β-blockers on left ventricular function using speckle-tracking echocardiography after 1 year of treatment in patients with ATTRwt-CM. Methods and Results: We included 46 patients (median age, 78 years) with ATTRwt-CM confirmed via biopsy. We analyzed laboratory and echocardiographic data, including global longitudinal strain (GLS) to determine left ventricular strain, using 2D speckle-tracking echocardiography and compared the changes in these parameters before and 1 year after treatment with tafamidis between 24 patients who did not receive β-blockers and 22 patients who received β-blockers. The absolute GLS deterioration was higher in patients taking β-blockers by a mean of 0.48±1.55% compared with -0.68±1.65% in patients not taking β-blockers (P=0.0181). However, other conventional heart failure medications showed no change in the GLS. Conclusions: Left ventricular function may deteriorate with the use of β-blockers in patients with ATTRwt-CM treated with tafamidis for 1 year.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.